Destiny Pharma plc (GB:DEST) has released an update.
Destiny Pharma plc, a clinical-stage biotech company, successfully passed all resolutions during its Annual General Meeting, as reported on June 12, 2024. The company, known for its innovative approach to preventing life-threatening infections, has two late-stage products in development: XF-73 nasal gel and NTCD-M3, targeting post-surgical and hospital-acquired infections respectively. Shareholders can access detailed voting results on the company’s website.
For further insights into GB:DEST stock, check out TipRanks’ Stock Analysis page.
